Companies

sells its Galactic bio-solvents line (Galasolv) alongside the company's broader lactic acid and food-grade lactates portfolio, distributed via the ChemPoint and Comindex (IMPAG Group) networks across European industrial coatings and cleaning customers.

subsidiary of the listed Tianmu Pharmaceutical group; received a renewed drug-manufacturing license from the Anhui Provincial Drug Administration (valid through December 31, 2030) covering raw-material-drug production of menthol and mint-sucrose oil.

its sunflower- and grape-seed-derived cocoa-free confectionery technology is now distributed across North America by Cargill under the NextCoa brand, announced May 2026 — a global B2B alliance positioning cocoa-free chocolate as a price-stable, climate-resilient alternative to African cocoa supply.

ferments British barley and Mediterranean carob into a cocoa-free chocolate alternative, sold direct-to-consumer as Waim! bars and pursuing B2B supply deals with larger confectionery manufacturers.

OncoIndx / OncoTarget / Prime Plus — Multi-omic oncology product suite.

develops companion diagnostics and genomic testing paired with domestic and global oncology drug approvals, part of China's growing precision-oncology testing base.

its Accelerate Pheno system runs rapid phenotypic antibiotic susceptibility testing directly from a positive blood culture, with clinical performance documented across multiple peer-reviewed studies.

develops polyurethane-based surgical adhesive and sealant technology for tissue bonding applications.

develops AI-based eye-screening technology, including diabetic-retinopathy and broader ophthalmic disease detection, as part of China's growing ophthalmic AI diagnostics base.

received FDA authorization for EndeavorOTC in June 2024, the first FDA clearance of a digital treatment for adult ADHD delivered through a video game, and launched ENDEAVORRIDE in Japan with Shionogi in June 2026 as the first adjunctive therapy app for pediatric ADHD in that market.

an API chemical-development CDMO running immobilised-lipase (CALB) biocatalysis and cGMP flow-hydrogenation capability for late-stage sponsor process development.

develops magnetically controlled capsule endoscopy, in which an external magnet steers the swallowed capsule's position and orientation for a more complete GI examination than passive transit alone.

vepdegestrant (ARV-471) is a first-in-class estrogen-receptor PROTAC approaching FDA approval for ER+ breast cancer, co-developed with Pfizer; it is the modality's lead regulatory asset and would be the first approved targeted-protein-degradation drug.

a biocatalysis CDMO whose enzyme-catalysed routes serve steroid and broader API synthesis, supporting the biocatalytic shift from traditional chemical semi-synthesis.

develops an AI-driven bionic arm combining neural interfaces and advanced robotics to restore natural, intuitive arm and hand function.

a major domestic in-vitro diagnostics company, participates in China's antibiotic-susceptibility and broader IVD testing market.

draws a microsample of blood at retail locations rather than through home self-collection, and recently launched its BetterWay GLP-1 blood-testing panel at retail sites in Austin and Temple, Texas.

received FDA clearance for SleepioRx in August 2024 and for DaylightRx in September 2024, the first FDA-cleared non-drug treatment for generalized anxiety disorder, and raised $23.7 million in February 2026 to scale commercial expansion following new CMS reimbursement codes for digital mental health treatments.

continues to innovate with a non-PFAS lumen coating method and its HYDAK hydrophilic coating line for guidewires and peripheral vascular devices, responding to regulatory pressure to eliminate PFAS from medical surfaces.

supplies CryoStor and BloodStor biopreservation media and CellSeal CryoCase cold-chain packaging, the cryopreservation technology layer used across biobanking and cell/gene-therapy manufacturing.

its BIOMONITOR IV insertable cardiac monitor adds artificial-intelligence-assisted arrhythmia detection, building on the company's record as the first to implant a leadless pacemaker in the US.

its LUX-Dx insertable cardiac monitor line has cleared multiple FDA 510(k)s, though the company issued an FDA recall in 2026 addressing a LUX-Dx II monitoring-system malfunction.

Intelligent bionic hand — Strong reported sales growth.

launched Brij-Seal, expanding its incision-management portfolio with an advanced wound sealant engineered for strength, flexibility and biocompatibility, alongside its BRIJJIT product line securing an ECAT government-procurement listing.

reported initial Phase 1 first-in-human results for cemsidomide (CFT7455), a novel MonoDAC IKZF1/3 degrader, in patients with non-Hodgkin's lymphoma.

its CapsoCam Plus capsule endoscopy device has cleared approval for pediatric use, with the company reporting its first-quarter 2026 financial results as a public company.

launched Caris Detect and introduced AI-powered molecular insights for NSCLC patients, alongside AI models predicting brain-metastases risk in breast and lung cancer, its Caris ChromoSeq assay, and its Caris Assure blood-based test.

received FDA clearance to initiate a Phase 2 clinical trial of CK0801, an allogeneic cord-blood-derived Treg, for aplastic anaemia, extending Treg therapy beyond oncology into autoimmune haematology.

its Simcyp Simulator, a PBPK platform built over 25 years with a consortium of more than 35 pharmaceutical companies, released Version 25 in early 2026 building on EMA qualification, and Certara reported that Simcyp simulation results replaced ten human trials for the chronic myeloid leukemia therapy asciminib.

operated in Shenzhen, CNGB is among the world's largest biological-resource repositories, storing biospecimens and genomic resources as part of China's national biotechnology infrastructure.

launched Rejoyn in April 2024, the first-and-only prescription digital therapeutic cleared by the FDA for the adjunctive treatment of major depressive disorder symptoms, and expanded it to Great Britain in June 2025.

secured a new CMS reimbursement code (L6700) for upper-limb pattern recognition prostheses in January 2025 and was acquired by Hanger, Inc. in 2025; its COMPLETE CONTROL System Gen2 uses AI and machine learning for prosthesis control.

runs a clinical metagenomic whole-genome-sequencing platform with dedicated gastroenterological, gastric and metabolic diagnostic panels for clinical use.

its biomimetic hemostatic gel, marketed as TraumaGel, showed promising results for treating penetrating traumatic brain injury in a study with the Walter Reed Army Institute of Research, received an Innovative Technology contract from Vizient, and was named to Fast Company's Most Innovative Companies list for 2026.

its TearX platform recently reported interim clinical study results showing excellent correlation between its Red Eye test and quantitative ELISA testing, alongside French regulatory approval and a new clinical study initiated with Alyatec.

received FDA approval and launched MarginProbe 2, a next-generation radiofrequency-spectroscopy probe for intraoperative breast-tumor margin assessment in breast-conserving surgery, continuing the MarginProbe technology line through a pivotal trial for the upgraded device.

procures and processes human biospecimens, including its "Vintage Collection" of legacy specimens, as a contract service for pharma and biotech genomic-biomarker and companion-diagnostic (CDx) programs.

holds a patent for "methods and compositions for synthetic biomarkers" and presented early-cancer-detection data at AACR annual meetings and in Nature Communications, engineering constructs that localize to tumor tissue and amplify an otherwise sub-detectable signal.

its ID-Cap ingestible event marker confirms medication ingestion for adherence monitoring, with active clinical studies including a UCLA study on HIV care and the University of Colorado's QUANTI-TAF study.

offers a broad mail-in test menu spanning vitamin D and inflammation, cholesterol and lipids, heart health, food sensitivity and thyroid testing.

launched Cancerguard, which the company calls the first-of-its-kind multi-cancer early detection blood test.

markets a portfolio of corticosteroid APIs, with a long-standing position in adrenal-cortical and reproductive-hormone manufacturing.

launched HydroMark, its proprietary hydrophilic coating platform, at MD&M West in January 2026, positioning it as an independent alternative to OEMs and CMOs amid consolidation among coating suppliers, building on more than 25 years in medical device coating services.

its SimpleScreen colorectal-cancer blood test met all primary and secondary endpoints (85% sensitivity for CRC, 22% for advanced precancerous lesions), alongside separate multiomic lung-cancer screening data.

launched LUBRITEQ, a new high-performance hydrophilic coating solution, in February 2026, positioned as a CDMO partner uniting advanced chemistry, device engineering and customer-first partnerships.

announced a partnership to develop lactic acid on the European market, submitted permit applications for a new biorefinery in Port-Jérôme-sur-Seine, France, and partnered with Tereos on a wheat-to-bioplastics green-chemistry initiative described as a first in Europe.

supplies sterile corticosteroid APIs such as budesonide (oral and respiratory) for inhalation and other sterile applications, under the Minakem group.

its splenic neuromodulation therapy for rheumatoid arthritis received FDA approval to progress to the randomized, controlled stage of clinical feasibility testing, alongside a new Chief Medical Officer appointment.

participates in China's precision-oncology genomic testing market as part of the country's growing domestic multi-omic testing base.

presented preclinical data for GNTI-122, its autologous antigen-specific engineered Treg lead, an approach designed to restore tolerance with tissue-restricted specificity.

develops activity-based nanosensors whose protease-cleavable substrates release reporter fragments detectable in urine, with the underlying fluorogenic-substrate and protease-detection chemistry documented in peer-reviewed journals and multiple patent filings.

reported full NHS-Galleri trial results at the 2026 ASCO Annual Meeting showing a substantial reduction in stage IV cancer diagnoses and a four-fold higher cancer detection rate, presented Pathfinder 2 results from more than 35,000 participants, and has submitted an FDA PMA application for Galleri.

its Spectralis OCT platform, originally built for ophthalmology, is now widely used as a research and clinical tool for OCT-based structural and vascular biomarkers linked to neurodegenerative disease, documented across multiple 2026 publications including JAMA Ophthalmology.

reported 2025 profit growth of 205.92%, describing itself as the lactic acid sector leader with a full-industry-chain layout opening new growth space, and its 75,000-ton PLA project was expected to begin production in mid-2026.

recently received FDA 510(k) clearance (K253704) for iPredict DR, AI-powered software for automated diabetic retinopathy screening.

developed the iKnife (Intelligent Knife), which uses rapid evaporative ionization mass spectrometry (REIMS) to analyze the aerosol generated by electrosurgical cutting in real time and identify tissue type from its lipidomic signature, commercialized in partnership with Waters Corporation's mass-spectrometry platforms.

continued to expand evidence for its next-generation hypoglossal nerve stimulation therapy for obstructive sleep apnea, presenting final ADHERE registry results covering more than 5,000 patients and the OSPREY randomized trial broadening neurostimulation options at SLEEP 2026 in June.

closed its acquisition of Precision Coating in January 2025, adding proprietary GlideLine fluoropolymer coatings, MICRALOX anodic coatings and IonGuard technology, and showcased an expanded coatings and R&D capability spanning PTFE, hydrophilic, parylene and advanced surface-modification technologies at MD&M West 2026.

its OPRA implant system, an osseointegration technology that anchors a prosthesis directly to bone, demonstrated superior treatment outcomes in a two-year follow-up study by Walter Reed National Military Medical Center, and the company is expanding implant system access in Ukraine.

its stimulated Raman histology (SRH) system generates digital, pathologist-quality images of brain-tumor tissue in the operating room, aimed at central-nervous-system surgery where frozen-section turnaround is a bottleneck.